Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.

Dall'Era MA, deVere-White R, Rodriguez D, Cress R.

Eur Urol Focus. 2018 May 4. pii: S2405-4569(18)30106-8. doi: 10.1016/j.euf.2018.04.016. [Epub ahead of print]

PMID:
29735368
2.

Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy.

Ho PY, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, Hu Z, Wun T, Lara PN, DeVere White RW, Chen HW, Yu AM.

J Pharmacol Exp Ther. 2018 Jun;365(3):494-506. doi: 10.1124/jpet.118.247775. Epub 2018 Mar 30.

PMID:
29602831
3.

Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model.

Long Q, Lin TY, Huang Y, Li X, Ma AH, Zhang H, Carney R, Airhart S, Lam KS, deVere White RW, Pan CX, Li Y.

Nanomedicine. 2018 Apr;14(3):789-799. doi: 10.1016/j.nano.2017.12.014. Epub 2018 Jan 6.

PMID:
29317342
4.

The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.

Zeng SX, Zhu Y, Ma AH, Yu W, Zhang H, Lin TY, Shi W, Tepper CG, Henderson PT, Airhart S, Guo JM, Xu CL, deVere White RW, Pan CX.

Clin Cancer Res. 2017 Nov 1;23(21):6580-6591. doi: 10.1158/1078-0432.CCR-17-0033. Epub 2017 Aug 14.

5.

The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.

D'Abronzo LS, Bose S, Crapuchettes ME, Beggs RE, Vinall RL, Tepper CG, Siddiqui S, Mudryj M, Melgoza FU, Durbin-Johnson BP, deVere White RW, Ghosh PM.

Oncogene. 2017 Nov 16;36(46):6359-6373. doi: 10.1038/onc.2017.233. Epub 2017 Jul 24.

6.

Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.

Jian C, Tu MJ, Ho PY, Duan Z, Zhang Q, Qiu JX, DeVere White RW, Wun T, Lara PN, Lam KS, Yu AX, Yu AM.

Oncotarget. 2017 May 9;8(19):30742-30755. doi: 10.18632/oncotarget.16372.

7.

Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact?

Chandrasekar T, Pugashetti N, Durbin-Johnson B, Dall'Era MA, Evans CP, deVere White RW, Yap SA.

Bladder Cancer. 2016 Oct 27;2(4):441-448. doi: 10.3233/BLC-160071.

8.

Determinants of Survival for Adolescents and Young Adults with Urothelial Bladder Cancer: Results from the California Cancer Registry.

Lara J, Brunson A, Keegan TH, Malogolowkin M, Pan CX, Yap S, deVere White R.

J Urol. 2016 Nov;196(5):1378-1382. doi: 10.1016/j.juro.2016.05.082. Epub 2016 May 18.

9.

Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer.

Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS.

Nanotechnology. 2016 Oct 21;27(42):425103. doi: 10.1088/0957-4484/27/42/425103. Epub 2016 Sep 19.

10.

Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer.

Lin TY, Li Y, Liu Q, Chen JL, Zhang H, Lac D, Zhang H, Ferrara KW, Wachsmann-Hogiu S, Li T, Airhart S, deVere White R, Lam KS, Pan CX.

Biomaterials. 2016 Oct;104:339-51. doi: 10.1016/j.biomaterials.2016.07.026. Epub 2016 Jul 22.

11.

Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy.

Vinall RL, Tepper CG, Ripoll AA, Gandour-Edwards RF, Durbin-Johnson BP, Yap SA, Ghosh PM, deVere White RW.

Genes Cancer. 2016 Mar;7(3-4):86-97. doi: 10.18632/genesandcancer.103.

12.

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.

Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN Jr, Pan CX.

Cancer. 2016 Jun 15;122(12):1897-904. doi: 10.1002/cncr.29927. Epub 2016 Mar 28.

13.

miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.

Shi XB, Ma AH, Xue L, Li M, Nguyen HG, Yang JC, Tepper CG, Gandour-Edwards R, Evans CP, Kung HJ, deVere White RW.

Cancer Res. 2015 Dec 15;75(24):5309-17. doi: 10.1158/0008-5472.CAN-14-0795. Epub 2015 Nov 16.

14.

The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence.

Mooso BA, Vinall RL, Mudryj M, Yap SA, deVere White RW, Ghosh PM.

J Urol. 2015 Jan;193(1):19-29. doi: 10.1016/j.juro.2014.07.121. Epub 2014 Aug 23. Review.

15.

Forecasting nutrition research in 2020.

Hackman RM, Aggarwal BB, Applebaum RS, deVere White RW, Dubick MA, Heber D, Ito T, Johnson GH, Keen CL, Winters BL, Stohs SJ.

J Am Coll Nutr. 2014;33(4):340-6. doi: 10.1080/07315724.2014.943113. Epub 2014 Aug 21. No abstract available.

PMID:
25144361
16.

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.

Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN Jr, DeVere White RW, Gao AC, Evans CP.

Oncogene. 2014 Sep 4;33(36):4521-30. doi: 10.1038/onc.2014.25. Epub 2014 Mar 24.

17.

No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period.

Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA.

Cancer. 2014 Mar 15;120(6):818-23. doi: 10.1002/cncr.28485. Epub 2013 Nov 20.

18.

miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.

Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, deVere White RW, Kung HJ.

Oncogene. 2014 May 8;33(19):2495-503. doi: 10.1038/onc.2013.200. Epub 2013 Jun 3.

19.

Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.

Amir S, Ma AH, Shi XB, Xue L, Kung HJ, Devere White RW.

PLoS One. 2013 Apr 9;8(4):e61064. doi: 10.1371/journal.pone.0061064. Print 2013.

20.

Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells.

Shi XB, Xue L, Ma AH, Tepper CG, Gandour-Edwards R, Kung HJ, deVere White RW.

Oncogene. 2013 Aug 29;32(35):4130-8. doi: 10.1038/onc.2012.425. Epub 2012 Oct 15.

21.

An interview with Ralph W. deVere White. Interview by John Fitzpatrick.

deVere White RW.

BJU Int. 2012 Nov;110(9):1221-2. doi: 10.1111/j.1464-410X.2012.11606.x. No abstract available.

23.

Functional p53 determines docetaxel sensitivity in prostate cancer cells.

Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW, Gao AC.

Prostate. 2013 Mar;73(4):418-27. doi: 10.1002/pros.22583. Epub 2012 Sep 19.

24.

Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization.

Mooso BA, Vinall RL, Tepper CG, Savoy RM, Cheung JP, Singh S, Siddiqui S, Wang Y, Bedolla RG, Martinez A, Mudryj M, Kung HJ, Devere White RW, Ghosh PM.

Endocr Relat Cancer. 2012 Nov 9;19(6):759-77. doi: 10.1530/ERC-12-0171. Print 2012 Dec.

25.

Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression.

Vinall RL, Chen JQ, Hubbard NE, Sulaimon SS, Shen MM, Devere White RW, Borowsky AD.

Dis Model Mech. 2012 Nov;5(6):914-20. doi: 10.1242/dmm.008995. Epub 2012 Apr 12.

26.

In vivo testing of a prototype system providing simultaneous white light and near infrared autofluorescence image acquisition for detection of bladder cancer.

Jacobson MC, deVere White R, Demos SG.

J Biomed Opt. 2012 Mar;17(3):036011. doi: 10.1117/1.JBO.17.3.036011.

PMID:
22502569
27.

MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth.

Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, deVere White RW, Kung HJ, Evans CP, Gao AC.

PLoS One. 2012;7(3):e32832. doi: 10.1371/journal.pone.0032832. Epub 2012 Mar 30.

28.

Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.

Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP 3rd, Crawford ED, Thompson IM Jr, Klein EA.

Urology. 2012 Mar;79(3):633-7. doi: 10.1016/j.urology.2011.11.019.

29.

Nucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples.

Kearney MF, Lee K, Bagni RK, Wiegand A, Spindler J, Maldarelli F, Pinto PA, Linehan WM, Vocke CD, Delviks-Frankenberry KA, Devere White RW, Del Prete GQ, Mellors JW, Lifson JD, Kewalramani VN, Pathak VK, Coffin JM, Le Grice SF.

Adv Virol. 2011;2011:272193. doi: 10.1155/2011/272193. Epub 2011 Nov 17.

30.

A model for rural oncology.

Heifetz LJ, Christensen SD, Devere-White RW, Meyers FJ.

J Oncol Pract. 2011 May;7(3):168-71. doi: 10.1200/JOP.2010.000167.

31.

Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.

Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL, deVere White RW, Ghosh PM.

Clin Cancer Res. 2011 Oct 1;17(19):6218-28. doi: 10.1158/1078-0432.CCR-11-1548. Epub 2011 Aug 15.

32.

Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers.

Hua S, An HJ, Ozcan S, Ro GS, Soares S, DeVere-White R, Lebrilla CB.

Analyst. 2011 Sep 21;136(18):3663-71. doi: 10.1039/c1an15093f. Epub 2011 Jul 21.

33.

MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.

Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW.

Int J Cancer. 2012 Jun 1;130(11):2526-38. doi: 10.1002/ijc.26256. Epub 2011 Dec 2.

34.

Influence of short polyglutamine tracts and p160 coactivators on the transactivation of the androgen receptor.

Shi XB, Xue L, Shi D, deVere White RW.

Cancer Biother Radiopharm. 2011 Apr;26(2):191-201. doi: 10.1089/cbr.2010.0888.

35.

Secondary malignancies among nonseminomatous germ cell tumor cancer survivors.

Chamie K, Kurzrock EA, Evans CP, Litwin MS, Koppie TM, Wootton-Gorges SL, Boone JM, Lara PN Jr, Devere White RW.

Cancer. 2011 Sep 15;117(18):4219-30. doi: 10.1002/cncr.26038. Epub 2011 Mar 15.

36.

Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer.

deVere White RW, Tsodikov A, Stapp EC, Soares SE, Fujii H, Hackman RM.

Nutr Cancer. 2010;62(8):1036-43. doi: 10.1080/01635581.2010.492085.

37.

Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.

Chen L, Siddiqui S, Bose S, Mooso B, Asuncion A, Bedolla RG, Vinall R, Tepper CG, Gandour-Edwards R, Shi X, Lu XH, Siddiqui J, Chinnaiyan AM, Mehra R, Devere White RW, Carraway KL 3rd, Ghosh PM.

Cancer Res. 2010 Jul 15;70(14):5994-6003. doi: 10.1158/0008-5472.CAN-09-4440. Epub 2010 Jun 29.

38.

The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy.

Hellenthal NJ, Ramirez ML, Evans CP, Devere White RW.

BJU Int. 2010 Feb;105(4):485-8. doi: 10.1111/j.1464-410X.2009.08905.x. Epub 2009 Oct 22.

39.

Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology.

Lotan Y, Kamat AM, Porter MP, Robinson VL, Shore N, Jewett M, Schelhammer PF, deVere White R, Quale D, Lee CT; Bladder Cancer Think Tank; Bladder Cancer Advocacy Network; Society of Urologic Oncology.

Cancer. 2009 Sep 15;115(18):4096-103. doi: 10.1002/cncr.24463.

40.

MicroRNAs and their potential for translation in prostate cancer.

DeVere White RW, Vinall RL, Tepper CG, Shi XB.

Urol Oncol. 2009 May-Jun;27(3):307-11. doi: 10.1016/j.urolonc.2009.01.004.

41.

A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).

deVere White RW, Lara PN Jr, Goldman B, Tangen CM, Smith DC, Wood DP Jr, Hussain MH, Crawford ED.

J Urol. 2009 Jun;181(6):2476-80; discussion 2480-1. doi: 10.1016/j.juro.2009.01.115. Epub 2009 Apr 16.

42.

Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004.

Hellenthal NJ, Ramírez ML, Evans CP, deVere White RW, Koppie TM.

J Urol. 2009 Jun;181(6):2490-5. doi: 10.1016/j.juro.2009.02.031. Epub 2009 Apr 16.

PMID:
19371902
43.

The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer.

deVere White RW, Katz MH, Steinberg GD.

J Urol. 2009 May;181(5):1994-7. doi: 10.1016/j.juro.2009.02.052. Epub 2009 Mar 14. Review. No abstract available.

PMID:
19286209
44.

Sociodemographic factors associated with nephrectomy in patients with metastatic renal cell carcinoma.

Hellenthal NJ, Chamie K, Ramirez ML, deVere White RW.

J Urol. 2009 Mar;181(3):1013-8; discussion 1018-9. doi: 10.1016/j.juro.2008.10.159. Epub 2009 Jan 16.

PMID:
19150554
45.

The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer.

Chamie K, Ghosh PM, Koppie TM, Romero V, Troppmann C, deVere White RW.

Am J Transplant. 2008 Dec;8(12):2668-73. doi: 10.1111/j.1600-6143.2008.02430.x. Epub 2008 Oct 6.

46.

Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.

Shi XB, Xue L, Zou JX, Gandour-Edwards R, Chen H, deVere White RW.

Prostate. 2008 Dec 1;68(16):1816-26. doi: 10.1002/pros.20849.

PMID:
18780293
47.

Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.

Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM.

Oncogene. 2008 Nov 27;27(56):7106-17. doi: 10.1038/onc.2008.318. Epub 2008 Sep 8.

48.

Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer.

Chamie K, DeVere White RW, Lee D, Ok JH, Ellison LM.

Cancer. 2008 Nov 1;113(9):2464-70. doi: 10.1002/cncr.23695.

49.

Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells.

Devlin HL, Mack PC, Burich RA, Gumerlock PH, Kung HJ, Mudryj M, deVere White RW.

Mol Cancer Res. 2008 May;6(5):808-18. doi: 10.1158/1541-7786.MCR-07-2027.

50.

Cancerous miRNAs and their regulation.

Shi XB, Tepper CG, deVere White RW.

Cell Cycle. 2008 Jun 1;7(11):1529-38. Epub 2008 Mar 20. Review.

PMID:
18469525

Supplemental Content

Loading ...
Support Center